key: cord-0698487-675v58x8
authors: Ohl, Michael E.; Miller, Donald R.; Lund, Brian C.; Kobayashi, Takaaki; Richardson Miell, Kelly; Beck, Brice F.; Alexander, Bruce; Crothers, Kristina; Vaughan Sarrazin, Mary S.
title: Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19
date: 2021-07-15
journal: JAMA Netw Open
DOI: 10.1001/jamanetworkopen.2021.14741
sha: 3fdede96088ac9085343fdc46df3d1a46f8c99de
doc_id: 698487
cord_uid: 675v58x8

IMPORTANCE: Randomized clinical trials have yielded conflicting results about the effects of remdesivir therapy on survival and length of hospital stay among people with COVID-19. OBJECTIVE: To examine associations between remdesivir treatment and survival and length of hospital stay among people hospitalized with COVID-19 in routine care settings. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from the Veterans Health Administration (VHA) to identify adult patients in 123 VHA hospitals who had a first hospitalization with laboratory-confirmed COVID-19 from May 1 to October 8, 2020. Propensity score matching of patients initiating remdesivir treatment to control patients who had not initiated remdesivir treatment by the same hospital day was used to create the analytic cohort. EXPOSURES: Remdesivir treatment. MAIN OUTCOMES AND MEASURES: Time to death within 30 days of remdesivir treatment initiation (or corresponding hospital day for matched control individuals) and time to hospital discharge with time to death as a competing event. Associations between remdesivir treatment and these outcomes were assessed using Cox proportional hazards regression in the matched cohort. RESULTS: The initial cohort included 5898 patients admitted to 123 hospitals, 2374 (40.3%) of whom received remdesivir treatment (2238 men [94.3%]; mean [SD] age, 67.8 [12.8] years) and 3524 (59.7%) of whom never received remdesivir treatment (3302 men [93.7%]; mean [SD] age, 67.0 [14.4] years). After propensity score matching, the analysis included 1172 remdesivir recipients and 1172 controls, for a final matched cohort of 2344 individuals. Remdesivir recipients and matched controls were similar with regard to age (mean [SD], 66.6 [14.2] years vs 67.5 [14.1] years), sex (1101 men [93.9%] vs 1101 men [93.9%]), dexamethasone use (559 [47.7%] vs 559 [47.7%]), admission to the intensive care unit (242 [20.7%] vs 234 [19.1%]), and mechanical ventilation use (69 [5.9%] vs 45 [3.8%]). Standardized differences were less than 10% for all measures. Remdesivir treatment was not associated with 30-day mortality (143 remdesivir recipients [12.2%] vs 124 controls [10.6%]; log rank P = .26; adjusted hazard ratio [HR], 1.06; 95% CI, 0.83-1.36). Results were similar for people receiving vs not receiving dexamethasone at remdesivir initiation (dexamethasone recipients: adjusted HR, 0.93; 95% CI, 0.64-1.35; nonrecipients: adjusted HR, 1.19; 95% CI, 0.84-1.69). Remdesivir recipients had a longer median time to hospital discharge compared with matched controls (6 days [interquartile range, 4-12 days] vs 3 days [interquartile range, 1-7 days]; P < .001). CONCLUSIONS AND RELEVANCE: In this cohort study of US veterans hospitalized with COVID-19, remdesivir treatment was not associated with improved survival but was associated with longer hospital stays. Routine use of remdesivir may be associated with increased use of hospital beds while not being associated with improvements in survival.

Malignancy C01.X, C02.X, C03.X, C04.X, C05.X, C06.X, C07.X, C08.X, C09.X, C10.X, C11.X, C12.X, C13.X, C14.X, C15.X, C16.X, C17.X, C18.X, C19.X, C20.X, C21.X, C22.X, C23.X, C24.X, C25.X, C26.X, C30.X, C31.X, C32.X, C33.X, C34.X, C37.X, C38.X, C39.X, C40.X, C41.X, C43.X, C45.X, C46.X, C47.X, C48.X, C49.X, C50.X, C51.X, C52.X, C53.X, C54.X, C55.X, C56.X, C57.X, C58.X, C60.X, C61.X, C62.X, C63.X, C64.X, C65.X, C66.X, C67.X, C68.X, C69.X, C70.X, C71.X, C72.X, C73.X, C74.X, C75.X, C76.X, C81.X, C82.X, C83.X, C84.X, C85.X, C88.X, C90.X, C91.X, C92.X, C93.X, C94.X, C95.X, C96.X, C97.X Myocardial infarction I21. Variables for fact of ventilation and day of ventilation were created based on procedure codes, medications used in intubation and ventilation, and natural language processing of note text.

Approach to propensity score matching by hospital day

To estimate propensity models for remdesivir initiation, a separate record was created for each day of acute stay for each patient until the patient was discharged, became ineligible for remdesivir initiation due to elevated ALT/AST or eGFR<30, or initiated remdesivir. In addition, days of care on which key predictors of remdesivir were missing were excluded (e.g., missing eGFR Each patient who initiated remdesivir (i.e., "cases") during the observation period was matched to a patient who had not initiated remdesivir as of the same day of stay (i.e.,

"controls"). The matching algorithm incorporated a novel approach using the nearest available

Mahalanobis metric within calipers representing one quarter of one standard deviation of the case propensity score. 3 This matching algorithm produces better patient covariate balance compared to nearest neighbor propensity matching or matching by mahalanobis distance calculated using only the propensity score. 1 Steps in the matching procedure are depicted in eFigure 1 below and include: 1) Identify a single randomly selected case (i.e., patients who initiated remdesivir), and assign an 'Index Day'

representing the day of stay of the first remdesivir dose; 2) for each index Day, identify potential controls, including all patients who had not yet initiated remdesivir as of the Index Day, were still eligible for remdesivir based on laboratory values (eGFR, ALT, AST), and had a propensity score within one quarter of one standard deviation of the logit of the case patient's propensity score, 3) if no candidate controls existed, the case patient was removed from analysis. If only one candidate control existed, that patient was selected and the match was considered final. If more than one candidate control existed, the mahalanobis distance between the case patient and the candidate controls was calculated based on the propensity score and patient characteristics prior to the index date. Specific characteristics included in the mahalanobis 

We sought to verify that hospitalizations for controls were related to COVID-19, as opposed to polymerase chain reaction test at admission, but that the providers caring for the patient found no clinical evidence of symptoms potentially related to COVID-19.

An alternative approach used marginal structural models (MSM) with stabilized inverse probability of treatment weights to estimate the relative impact of remdesivir on mortality and time to discharge. 4 WBCwhite blood cell eGFRestimated glomerular filtration rate ASTaspartate aminotransferase ALTalanine aminotransferase PCRpolymerase chain reaction ICUintensive care unit ACEangiotensin converting enzyme ARBangiotensin receptor blocker

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care

COVID-19: Shared Data Resource

A method/macro based on propensity score and mahalanobis distance to reduce bias in treatment comparison in observational study

Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men